Reported Earlier, Abbisko And AstraZeneca Jointly Advance Novel IO-TKI Combination Therapy Evaluating Lumipodlin Plus Osimertinib In EGFR-Mu
Reported Earlier, Abbisko And AstraZeneca Jointly Advance Novel IO-TKI Combination Therapy Evaluating Lumipodlin Plus Osimertinib In EGFR-Mutated PD-L1 Positive NSCLC Patients
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.